期刊文献+
共找到5篇文章
< 1 >
每页显示 20 50 100
双顺反子质粒DNA疫苗的研究
1
作者 陈锦荣 《生物制品快讯》 2002年第10期6-7,共2页
肿瘤疫苗是转移性癌化疗的有希望的替代品。为达到有效而安全,治疗性癌苗应特异性靶向转移性肿瘤细胞上表达的抗原。抗非何杰金氏B细胞淋巴瘤表达的特异性表面免疫球蛋白或其独特型的疫苗,它符合这些标难,因为原发的或转移的肿瘤细... 肿瘤疫苗是转移性癌化疗的有希望的替代品。为达到有效而安全,治疗性癌苗应特异性靶向转移性肿瘤细胞上表达的抗原。抗非何杰金氏B细胞淋巴瘤表达的特异性表面免疫球蛋白或其独特型的疫苗,它符合这些标难,因为原发的或转移的肿瘤细胞皆表达肿瘤特异性免疫球蛋白。使用小鼠38C13B细胞淋巴瘤作为一种模型系统设计了一种质粒DNA疫苗,它表达编码38C13肿瘤表面轻链和重链两种肿瘤免疫球蛋白(独特型)的双顺反子mRNA。为提高该质粒DNA疫苗的免疫原性,将小鼠轻重链的可变区与其人免疫球蛋白相应的稳定区相融合。另外,构建的真核类表达盒在体内得产生鼠/人嵌合型免疫球蛋白的高水平表达,及引起保护性免疫应答。用特有的SfiI限制位点快速克隆任一肿瘤特异的免疫球蛋白独特型区,产生的系列质粒构建物用以试验J区和/或人C区插入SfiI限制位点的差异,发现这样的差异对表达和免疫原性都有显著影响。原型独特型疫苗免疫小鼠产生了抗38C13肿瘤的保护性免疫应答。研究表明,双顺反子质粒DNA为基础的新疫苗可用于开发抗B细胞淋巴瘤的肿瘤特异性疫苗。 展开更多
关键词 肿瘤疫苗 转移性癌化疗 双顺反子质粒DNA疫苗 B细胞淋巴瘤
下载PDF
UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer 被引量:31
2
作者 Christoph Schulz Volker Heinemann +5 位作者 Andreas Schalhorn Nikolas Moosmann Thomas Zwingers Stefan Boeck Clemens Giessen Hans-Joachim Stemmler 《World Journal of Gastroenterology》 SCIE CAS CSCD 2009年第40期5058-5066,共9页
AIM: To investigate the correlation between uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1) gene polymorphisms and irinotecan-associated side effects and parameters of drug efficacy in patients with metastat... AIM: To investigate the correlation between uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1) gene polymorphisms and irinotecan-associated side effects and parameters of drug efficacy in patients with metastatic colorectal cancer (mCRC) receiving a low-dose weekly irinotecan chemotherapeutic regimen. METHODS: Genotypes were retrospectively evaluated by gene scan analysis on the ABI 310 sequencer of the TATAA box in the promoter region of the UGT1A1 gene in blood samples from 105 patients who had received 1st line irinotecan-based chemotherapy for mCRC. RESULTS: The distribution of the genotypes was as follows: wild type genotype (WT) (6/6 ) 39.0%, heterozygous genotype (6/7) 49.5%, and homozygous genotype (7/7) 9.5%. The overall response rate (OR) was similar between patients carrying the (6/7, 7/7) or the WT genotype (6/6) (44.3% vs 43.2%, P = 0.75). Neither time to progression [(TTP) 8.1 vs 8.2 mo, P = 0.97] nor overall survival [(OS) 21.2 vs 18.9 mo, P = 0.73] differed significantly in patients who carried the(6/6) when compared to the (6/7, 7/7) genotype. No significant differences in toxicity were observed: Grade 3 and 4 delayed diarrhoea [(6/7, 7/7) vs (6/6); 13.0% vs 6.2%, P =0.08], treatment delays [(6/7, 7/7) vs (6/6); 25.1% vs 19.3%, P = 0.24] or dose reductions [(6/7, 7/7) vs (6/6); 21.5% vs 27.2%, P = 0.07].CONCLUSION: This analysis demonstrates the non-significant influence of the UGT1A1 gene polymorphism on efficacy and rate of irinotecan-associated toxicity in mCRC patients receiving low-dose irinotecan based chemotherapy. 展开更多
关键词 IRINOTECAN Colorectal cancer UGTIA1 Gene polymorphism TOXICITY EFFICACY Delayed diarrhoea NEUTROPENIA
下载PDF
Response evaluation of chemotherapy in metastatic colorectal cancer by contrast enhanced ultrasound 被引量:16
3
作者 Ramin Schirin-Sokhan Ron Winograd +6 位作者 Christoph Roderburg Jhenee Bubenzer Nicole Cabral do ó Dorothee Guggenberger Hartmut Hecker Christian Trautwein Jens J W Tischendorf 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第6期541-545,共5页
AIM: To evaluate whether contrast enhanced ultra- sound (CEUS) might also be used for response predic- tion and early response evaluation in patients receiving bevacizumab based chemotherapy for metastasized colore... AIM: To evaluate whether contrast enhanced ultra- sound (CEUS) might also be used for response predic- tion and early response evaluation in patients receiving bevacizumab based chemotherapy for metastasized colorectal cancer.METHODS: Thirty consecutive patients with non prima- ry resectable liver metastases from colorectal cancer underwent CEUS before treatment (CEUS date 1) and before the second (CEUS date 2) and fourth (CEU5 date 3) cycle of bevacizumab based chemotherapy. Three parameters [PEAK, Time to peak (l-I-P) and RISE RATE]were correlated with radiological response.RESULTS: For neoadjuvant purpose a reduction of tu- mour mass was required to assume clinical response. Based on these response criteria there was a significant (P 〈 0.001) correlation in TTP between metastases of responders (9.08 s) and non-responders (14.76 s) ar- chived on CEUS date 1. By calculating a standardized quotient (metastases divided by normal liver tissue) we were able to define a cut off, predicting response with a sensitivity of 92.3 % and a specificity of 100 %. To reflect a palliative intention only those patients with progressive disease were classified as non-responders. In this stetting -FI-P was also significantly (P 〈 0.01) dif- ferent between responders and non-responders. In con- trast, Peak and Rise rate did not show any significant difference between responder and non-responder. CONCLUSION: CEUS might serve as a surrogate mark- er to predict treatment response in patients with me- tastasized colorectal cancer who receive antiangiogenic therapy. 展开更多
关键词 Colorectal cancer Liver metastases Responseprediction to chemotherapy Contrast-enhanced ultra-sound BEVACIZUMAB
下载PDF
Successful treatment of multiple lung metastases of hepatocellular carcinoma by combined chemotherapy with docetaxel, cisplatin and tegafur/uracil 被引量:7
4
作者 Atsunori Tsuchiya Michitaka Imai +7 位作者 Hiroteru Kamimura Tadayuki Togashi Kouji Watanabe Kei-ichi Seki Toru Ishikawa Hironobu Ohta Toshiaki Yoshida Tomoteru Kamimura 《World Journal of Gastroenterology》 SCIE CAS CSCD 2009年第14期1779-1781,共3页
We report the successful treatment of multiple lung metastases after hepatic resection for hepatocellular carcinoma (HCC) with combined docetaxel, cisplatin (CDDP), and enteric-coated tegafur/uracil (UFT-E). A 68-year... We report the successful treatment of multiple lung metastases after hepatic resection for hepatocellular carcinoma (HCC) with combined docetaxel, cisplatin (CDDP), and enteric-coated tegafur/uracil (UFT-E). A 68-year-old man was diagnosed with multiple lung metastases of HCC 7 mo after partial hepatectomy for HCC. Oral UFT-E was given daily and docetaxel and CDDP were given intra-arterially (administered just before the bronchial arteries) every 2 wk via a subcutaneous injection port. One month after starting chemotherapy, levels of tumor marker, protein induced by vitamin K absence(PIVKA--), decreased rapidly,and after a further month, chest X-ray and computed tomography revealed the complete disappearance of multiple liver metastases. Two years after the combined chemotherapy, HCC recurred in the liver and was treated but no pulmonary recurrence occurred. In the absence of a standardized highly effective therapy, this combined chemotherapy with docetaxel, CDDP and UFT-E may be an attractive option for multiple lung metastases of HCC. 展开更多
关键词 Hepatocellular carcinoma DOCETAXEL Lungmetastasis CISPLATIN
下载PDF
Efficiency and safety of trastuzumab plus chemotherapy in Her-2 overexpressing metastatic breast cancer patients
5
作者 Jianfei Guo Zhaozhe Liu +4 位作者 Guojing Zhang Tao Han Fang Guo Yaling Han Xiaodong Xie 《The Chinese-German Journal of Clinical Oncology》 CAS 2014年第12期555-559,共5页
Objective: The aim of this study was to evaluate the safety and efficiency of combination of trastuzumab and chemotherapy as first line regimen in Her-2 overexpressing metastatic breast cancer (MBC) patients. The p... Objective: The aim of this study was to evaluate the safety and efficiency of combination of trastuzumab and chemotherapy as first line regimen in Her-2 overexpressing metastatic breast cancer (MBC) patients. The primary endpoint was overall response rate (ORR) and the second endpoint was clinical benefit rate (CBR) and toxcities. Methods: Estrogen recep- tor (ER) (-), progesterone receptor (PR) (-), Her-2 (+++) patients were included in the study. 126 eligible patients were divided into 2 groups, 51 of them were assigned to the Herceptin group (H group) and 75 of them were assigned to the Control group (C group). They were treated by commonly used chemotherapy regimens with or without trastuzumab. Results: Response rate (RR) of the H group and the C group were 51.0% and 24.0% separately, and the difference were statistically significant (P 〈 0.05). CBR of the two groups were 76.4% (H group) and 64.0% (C group), had significant difference (P 〈 0.05). Complete response rate (CRR) of the two groups were 21.5% and 6.6%, there were no significant difference between the two groups (P = 0.055). Grade 3-4 cardiac toxicity were recorded in 9 patients with trastuzumab plus chemotherapy (17.6%) and 4 patients with chemotherapy (5.4%), with no statistical significance (P = 0.054). In the subgroup of antharcycline-containing regimens, Grade 1-4 cardiac toxicity occurred in 9 patients in the trasutuzumab combining with antharcycline-containing regimens arm [herceptin plus anthracyciine contained chemotherapy (H + ACCT arm; 40.9%, g/22)], and 4 patients in the antharcycline- containing chemotherapy arm (ACCT arm; 12.5%, 4/32). There was statistical significant difference between the two arms (P 〈 0.05). Grade 3--4 cardiac toxicity, the occurance rates were 18.1% (4/22) in H + ACCT arm and 6.3% (2/32) in ACCT arm, and there was no significant statistical difference (P = 0.352). Grade 3-4 granulocytopenia in the H group and C group were 27.5% (14/51) and 26.7% (20/75), with no significant difference (P = 0.922). Conclusion: The efficiency of trastuzumab combining with chemotherapy using as first line regimen in Her-2 overexpressing MBC patients were exact. However, the long-term cardiac toxicity can be hidden troubles of trastuzumab using. 展开更多
关键词 HERCEPTIN metastatic breast cancer first-fine chemotherapy
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部